Rosnilimab phase 2b rheumatoid arthritis data to be presented at ACR

SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), whose stock has surged over 80% in the past six months and is currently trading near overbought levels according to InvestingPro analysis, announced Monday that complete data from its Phase 2b trial of rosnilimab in rheumatoid arthritis has been accepted for a late-breaking oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2025 in Chicago.

Professor Paul Emery from the University of Leeds will present the findings on October 29 during a morning session. According to the company’s press release, the presentation will detail the drug’s efficacy, safety profile, and translational proof of mechanism. The company maintains a strong financial position with a current ratio of 8.22, indicating robust liquidity to support its clinical programs.

Rosnilimab is designed to target pathogenic T cells involved in autoimmune and inflammatory diseases. The company describes it as a selective depleter of activated T cells while preserving naive T cells to maintain overall immune function.

Paul Lizzul, chief medical officer at AnaptysBio, stated that the Phase 2b trial demonstrated "JAK-like efficacy through six months that was durable for at least three months off-drug" along with a favorable safety profile.

AnaptysBio is also evaluating rosnilimab in a Phase 2 trial for ulcerative colitis. The company’s pipeline includes additional immunology candidates ANB033 for celiac disease and ANB101, both currently in Phase 1 trials.

The clinical-stage biotechnology company recently announced plans to separate its biopharma operations from its royalty assets by the end of 2026.

The information in this article is based on a company press release statement.

In other recent news, AnaptysBio announced plans to split into two independent, publicly traded companies by the end of 2026. The separation will result in a Royalty Management Company, which will manage royalties and milestone payments from collaborations, including those with GSK and Vanda Pharmaceuticals, and a Biopharma Company, which will focus on pipeline development, including drugs like rosnilimab. This strategic move has prompted analysts to adjust their outlooks on AnaptysBio. H.C. Wainwright raised its price target for the company from $38 to $59 while maintaining a Buy rating. Similarly, Leerink Partners increased its price target from $32 to $37 and maintained an Outperform rating. Additionally, Barclays initiated coverage on AnaptysBio with an Overweight rating, citing the potential of rosnilimab, a novel drug for rheumatoid arthritis. These developments reflect a positive sentiment among analysts regarding AnaptysBio’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.